Bioventus (BVS) Competitors $7.25 -0.24 (-3.20%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsFinancialsSEC FilingsShort InterestTrendsBuy This Stock BVS vs. LQDA, PRCT, LMAT, AORT, EYE, ENOV, CNMD, SSII, NVCR, and CDREShould you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include Liquidia Technologies (LQDA), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), SS Innovations International (SSII), NovoCure (NVCR), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. Bioventus vs. Its Competitors Liquidia Technologies PROCEPT BioRobotics LeMaitre Vascular Artivion National Vision Enovis CONMED SS Innovations International NovoCure Cadre Bioventus (NASDAQ:BVS) and Liquidia Technologies (NASDAQ:LQDA) are both medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Which has preferable earnings & valuation, BVS or LQDA? Bioventus has higher revenue and earnings than Liquidia Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$573.28M1.05-$33.54MN/AN/ALiquidia Technologies$14M168.86-$130.39M-$1.70-16.15 Does the media favor BVS or LQDA? In the previous week, Liquidia Technologies had 12 more articles in the media than Bioventus. MarketBeat recorded 12 mentions for Liquidia Technologies and 0 mentions for Bioventus. Liquidia Technologies' average media sentiment score of 1.24 beat Bioventus' score of 0.00 indicating that Liquidia Technologies is being referred to more favorably in the news media. Company Overall Sentiment Bioventus Neutral Liquidia Technologies Positive Which has more volatility & risk, BVS or LQDA? Bioventus has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Liquidia Technologies has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Is BVS or LQDA more profitable? Bioventus has a net margin of -0.03% compared to Liquidia Technologies' net margin of -732.17%. Bioventus' return on equity of 23.04% beat Liquidia Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-0.03% 23.04% 6.04% Liquidia Technologies -732.17%-232.96%-60.81% Do institutionals & insiders hold more shares of BVS or LQDA? 62.9% of Bioventus shares are owned by institutional investors. Comparatively, 64.5% of Liquidia Technologies shares are owned by institutional investors. 33.0% of Bioventus shares are owned by company insiders. Comparatively, 26.5% of Liquidia Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend BVS or LQDA? Liquidia Technologies has a consensus price target of $32.11, suggesting a potential upside of 16.94%. Given Liquidia Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Liquidia Technologies is more favorable than Bioventus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Liquidia Technologies 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryBioventus and Liquidia Technologies tied by winning 8 of the 16 factors compared between the two stocks. Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BVS vs. The Competition Export to ExcelMetricBioventusSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$619.27M$178.63M$2.56B$9.80BDividend YieldN/AN/A2.54%4.02%P/E Ratio14.982.5021.8126.59Price / Sales1.0531.80116.15168.41Price / Cash7.004.2023.4359.36Price / Book2.981.5236.146.68Net Income-$33.54M-$66.04M$26.72M$265.59M7 Day Performance2.40%1.27%2.10%3.42%1 Month Performance11.03%-11.56%2.09%1.09%1 Year PerformanceN/A183.04%32.72%23.84% Bioventus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BVSBioventus0.9101 of 5 stars$7.25-3.2%N/AN/A$619.27M$573.28M14.981,200LQDALiquidia Technologies3.6239 of 5 stars$27.19-0.4%$32.11+18.1%+190.2%$2.34B$19.32M-16.0250Positive NewsPRCTPROCEPT BioRobotics3.553 of 5 stars$41.12+4.5%$74.88+82.1%-49.9%$2.28B$224.50M-26.41430News CoveragePositive NewsLMATLeMaitre Vascular2.0971 of 5 stars$100.20+3.9%$97.60-2.6%+6.5%$2.26B$219.86M48.48490News CoveragePositive NewsAORTArtivion3.2525 of 5 stars$44.75+3.7%$40.63-9.2%+65.1%$2.11B$388.54M-106.501,600Analyst UpgradeInsider TradeEYENational Vision2.7437 of 5 stars$24.48+1.8%$24.73+1.0%+134.3%$1.94B$1.89B-136.1113,411Positive NewsENOVEnovis4.5371 of 5 stars$31.55+6.9%$51.00+61.7%-31.7%$1.80B$2.11B-2.217,367Positive NewsInsider TradeCNMDCONMED4.3961 of 5 stars$55.65+4.9%$59.80+7.5%-25.1%$1.72B$1.31B15.763,900News CoveragePositive NewsSSIISS Innovations InternationalN/A$7.28-3.4%N/AN/A$1.41B$20.65M0.004Positive NewsGap UpNVCRNovoCure4.155 of 5 stars$12.27+3.0%$28.79+134.6%-33.8%$1.38B$605.22M-7.901,488CDRECadre1.9227 of 5 stars$31.14+5.1%$31.50+1.1%-13.2%$1.27B$567.56M33.122,284 Related Companies and Tools Related Companies LQDA Alternatives PRCT Alternatives LMAT Alternatives AORT Alternatives EYE Alternatives ENOV Alternatives CNMD Alternatives SSII Alternatives NVCR Alternatives CDRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BVS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access